Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity

Nature Medicine

Volumn 16, Issue 3, 2010, Pages 339-345

  Flatz, Lukas ^a,b,c   Hegazy, Ahmed N ^b,d,e   Bergthaler, Andreas ^a,b,f   Verschoor, Admar ^b,g   Claus, Christina ^h   Fernandez, Marylise ^a   Gattinoni, Luca ⁱ   Johnson, Susan ^a   Kreppel, Florian ^j   Kochanek, Stefan ^j   Broek, Maries Van Den ^b,k   Radbruch, Andreas ^d,e   Lévy, Frédéric ^l,m   Lambert, Paul Henri ^a   Siegrist, Claire Anne ^a   Restifo, Nicholas P ⁱ   Löhning, Max ^b,d,e   Ochsenbein, Adrian F ^h   Nabel, Gary J ^c   Pinschewer, Daniel D ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b INSTITUTE OF EXPERIMENTAL IMMUNOLOGY   (Switzerland)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^f INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j UNIVERSITY OF ULM   (Germany)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^m DEBIOPHARM SA   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; OVALBUMIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; IN VIVO STUDY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TH1 CELL; VACCINIA VIRUS; VIRUS REPLICATION;

ANIMALS; ANTIBODY FORMATION; ARENAVIRIDAE INFECTIONS; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GENETIC VECTORS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; VACCINES, SYNTHETIC; VIRAL VACCINES;

ARENAVIRUS; HUMAN ADENOVIRUS TYPE 5; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; VACCINIA VIRUS;

EID: 77949275849     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2104     Document Type: Article

References (40)

1. Harari, A. et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 205, 63-77 (2008)
2. Peters, B.S. et al. Studies of a prophylactic HIV-1 vaccine candidate based on modifed vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 25, 2120-2127 (2007)
3. Darrah, P.A. et al. Multifunctional TH1 cells defne a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13, 843-850 (2007)
4. Kostense, S. et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18, 1213-1216 (2004)
5. Roberts, D.M. et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441, 239-243 (2006)
6. Buchmeier, M.J., Bowen, M.D. & Peters, C.J. Arenaviridae: The viruses and their replication. in Fields Virology (eds. Knipe, D.M. and Howley, P.M.) 1635-1668 (Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, 2001)
7. + T-cell memory. Nat. Med. 7, 913-919 (2001)
8. Pinschewer, D.D. et al. Kinetics of protective antibodies are determined by the viral surface antigen. J. Clin. Invest. 114, 988-993 (2004)
9. Pinschewer, D.D., Perez, M., Sanchez, A.B. & de la Torre, J.C. Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. Proc. Natl. Acad. Sci. USA 100, 7895-7900 (2003)
10. Flatz, L., Bergthaler, A., de la Torre, J.C. & Pinschewer, D.D. Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc. Natl. Acad. Sci. USA 103, 4663-4668 (2006)
11. Ciurea, A. et al. Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice. Proc. Natl. Acad. Sci. USA 96, 11964-11969 (1999)
12. Krebs, P., Scandella, E., Odermatt, B. & Ludewig, B. Rapid functional exhaustion and deletion of CTL following immunization with recombinant adenovirus. J. Immunol. 174, 4559-4566 (2005)
13. Lohning, M. et al. Long-lived virus-reactive memory T cells generated from purifed cytokine-secreting T helper type 1 and type 2 effectors. J. Exp. Med. 205, 53-61 (2008)
14. Steinhoff, U. et al. Antiviral protection by vesicular stomatitis virus-specifc antibodies in alpha/beta interferon receptor-defcient mice. J. Virol. 69, 2153-2158 (1995)
15. Pope, C. et al. Organ-specifc regulation of the CD8 T cell response to Listeria monocytogenes infection. J. Immunol. 166, 3402-3409 (2001)
16. Jensen, E.R., Shen, H., Wettstein, F.O., Ahmed, R. & Miller, J.F. Recombinant Listeria monocytogenes as a live vaccine vehicle and a probe for studying cell-mediated immunity. Immunol. Rev. 158, 147-157 (1997)
17. Kurts, C. et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc. Natl. Acad. Sci. USA 96, 12703-12707 (1999)
18. Hogquist, K.A. et al. T cell receptor antagonist peptides induce positive selection. Cell 76, 17-27 (1994)
19. Prevost-Blondel, A. et al. Tumor-infltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J. Immunol. 161, 2187-2194 (1998)
20. Steinman, R.M. Dendritic cells: versatile controllers of the immune system. Nat. Med. 13, 1155-1159 (2007)
21. + T cell tolerance. Immunity 18, 713-720 (2003)
22. Sevilla, N. et al. Immunosuppression and resultant viral persistence by specifc viral targeting of dendritic cells. J. Exp. Med. 192, 1249-1260 (2000)
23. Novak, A., Guo, C., Yang, W., Nagy, A. & Lobe, C.G. Z/EG, a double reporter mouse line that expresses enhanced green fuorescent protein upon Cre-mediated excision. Genesis 28, 147-155 (2000)
24. Seiler, P. et al. Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies: implications for passive and active immunization. J. Exp. Med. 187, 649-654 (1998)
25. de Lamballerie, X., Fulhorst, C.F. & Charrel, R.N. Prevalence of antibodies to lymphocytic choriomeningitis virus in blood donors in southeastern France. Transfusion 47, 172-173 (2007)
26. Lledo, L., Gegundez, M.I., Saz, J.V., Bahamontes, N. & Beltran, M. Lymphocytic choriomeningitis virus infection in a province of Spain: analysis of sera from the general population and wild rodents. J. Med. Virol. 70, 273-275 (2003)
27. Elbers, A.R. et al. Low prevalence of antibodies against the zoonotic agents Brucella abortus, Leptospira spp., Streptococcus suis serotype II, hantavirus, and lymphocytic choriomeningitis virus among veterinarians and pig farmers in the southern part of The Netherlands. Vet. Q. 21, 50-54 (1999)
28. Stephensen, C.B. et al. Prevalence of serum antibodies against lymphocytic choriomeningitis virus in selected populations from two U.S. cities. J. Med. Virol. 38, 27-31 (1992)
29. Fischer, S.A. et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N. Engl. J. Med. 354, 2235-2249 (2006)
30. Seaman, M.S. et al. Multiclade human immunodefciency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J. Virol. 79, 2956-2963 (2005)
31. Matter, M. et al. Decreased tumor surveillance after adoptive T-cell therapy. Cancer Res. 67, 7467-7476 (2007)
32. Valmori, D. et al. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J. Immunol. 164, 1125-1131 (2000)
33. Bellier, B. et al. DNA vaccines encoding retrovirus-based virus-like particles induce effcient immune responses without adjuvant. Vaccine 24, 2643-2655 (2006)
34. Wortmann, A. et al. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther. 16, 154-162 (2008)
35. Anton, L.C. et al. Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides. J. Immunol. 160, 4859-4868 (1998)
36. Hany, M. et al. Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia-recombinant virus expressing LCMV-WE nucleoprotein or glycoprotein. Eur. J. Immunol. 19, 417-424 (1989)
37. Probst, H.C. et al. Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression. J. Immunol. 171, 5415-5422 (2003)
38. Pircher, H., Burki, K., Lang, R., Hengartner, H. & Zinkernagel, R.M. Tolerance induction in double specifc T-cell receptor transgenic mice varies with antigen. Nature 342, 559-561 (1989)
39. 2m double knockout mice. J. Exp. Med. 185, 2043-2051 (1997)
40. Lore, K. et al. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus-and HIV-1-specifc T cell responses. J. Immunol. 171, 4320-4328 (2003)